Breakthrough Sepsis Pathogen Detection

Corporate Presentation August 2019 (NASDAQ: TTOO)




Forward-Looking Statements


This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ("we", "us", "our", "T2", "T2 Biosystems" or the "Company") and include those about T2's goals, strategies, plans, objectives, prospects, milestones, future operations, business and industry, anticipated product benefits, future events and conditions and potential scenarios. Such statements and those that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature identify forwardlooking statements for purposes of the federal securities laws or otherwise. Forward-looking statements address matters that involve risks and uncertainties. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, for example: (i) our status as an early commercialstage company and expectation to incur losses in the future; (ii) our ability to obtain marketing authorization from the FDA or regulatory clearance for additional product candidates in the United States or abroad; (iii) the market acceptance of our technology; (iv) our ability to timely and successfully develop and commercialize existing and future product candidates; (v) our lengthy and variable sales cycle and lack of sales history; (vi) our ability to successfully manage growth; (vii) federal, state and foreign regulatory requirements; (viii) our uncertain future capital needs and ability to raise future capital; (ix) dependence on third parties; (x) recruiting, training and retaining key personnel; (xi) competitive factors; (xii) manufacturing and other product risks; (xii) risks related to intellectual property; and (xiii) other risk factors included in our annual report on form 10-K filed with the Securities and Exchange Commission (SEC) on March 14, 2019 and other documents we file with the SEC from time to time. Accordingly, there are or will be important factors that could cause our actual results to differ materially from those indicated in these statements. The statements made herein speak only as of the date of this presentation. We do not undertake, and specifically disclaim, any obligation to update any forward-looking statements contained in this presentation.



Why Are We Here Today?

T2 has reached a tipping point for broad adoption of the T2Dx[®] technologies





Large Market	
Global unmet need	•

Revenue

Growth opportunity with attractive recurring model



Sepsis is a Deadly and Frustrating Global Problem

A recognized, but unsolved global crisis





Sepsis is a Deadly and Frustrating Global Problem

A critical part of the solution is now available






Represents the potential lives saved using the T2Direct Diagnostic to test high risk patients based on assumed levels of total annual patients assuming all high-risk sepsis patients are tested with T2Direct Diagnostics and assuming (i) 90% of high risk patients receive appropriate therapy within hours of the presentation of symptoms, (ii) a 50% mortality rate reduction for patients who receive rapid appropriate therapy, and (iii) that each new detected patient saves \$22,800. This slide contains T2's estimates, which are not based on historical results and constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.



CORPORATE PRESENTATION

The Facts About Sepsis

Most expensive hospital-treated condition in the U.S.



1. Liu, V., Escobar, G. J., Greene, J. D, et al. (2014). Hospital deaths in patients with sepsis from 2 independent cohorts. Jama, 312(1), 90-92.

2. Torio, C. M. and Moore, B. J. (2016). Statistical Brief# 204. Healthcare Cost and Utilization Project (HCUP). May.

3. McDermott, K. W., Elixhauser, A., Sun, R. (2017). Statistical Brief# 225. Healthcare Cost and Utilization Project (HCUP). June.

4. National Institute of General Medical Sciences. National Institutes of Health. Sepsis fact sheet. 2014.

5. Prescott, H. C., Osterholzer, J. J., Langa, K.M, et al. (2016). Late mortality after sepsis: propensity matched cohort study.

6. Centers for Disease Control and Prevention.


7. Gilbert, J. A. (2018). Sepsis care bundles: a work in progress. The Lancet Respiratory Medicine.

8. Mayr, F. B., Talisa, V. B., Balakumar, V., et al. (2017). Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. JAMA, 317(5), 530-531.



Sepsis Poses an Hourly Challenge that Relies on Probability-Based Protocols


Patient journey: Current pathway and empiric "process"





T2MR: New Standard in Detecting Sepsis Causing Pathogens

T2Direct Diagnostics provide faster and more accurate detection




>90% DETECTED¹


- 1. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., et al. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases, ciu959.
- 2. Clancy, C. J., & Nguyen, M. H. (2013). Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clinical infectious diseases, 56(9), 1284-1292.



3. Cockerill III, F. R., Wilson, J. W., Vetter, E.A., et al. (2004). Optimal testing parameters for blood cultures. Clinical Infectious Diseases, 38(12), 1724-1730.

The Blood Culture Divide






T2BACTERIA SPEED¹ AVERAGE TIME TO POSITIVE AND NEGATIVE RESULTS T2Bacteria 3.5 to 5 HRS BLOOD CULTURE 72-124 HRS

DAY 1

T2CANDIDA SPEED²



1. T2Bacteria Pivotal Clinical Study. Overall average sensitivity of 90% in prospective arm and 97% PPA in contrived arm.

DAY 4

2. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., et. al. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical infectious diseases, ciu959.

DAY 5




DAY 0

DAY 2

DAY 3

A Simple Change, an Immense Impact




- 1. T2Bacteria Clinical Pivotal Trial Data.
- 2. Buehler, S. S., Madison, B., Snyder, S. R., et al. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 29(1), 59-103.
- 3. Kumar, A., Ellis, P., Arabi, Y., et al. (2009). Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. CHEST Journal, 136(5), 1237-1248.
- 4. Represents the potential healthcare savings and lives saved using the T2Direct Diagnostic to test high risk patients based on assumed levels of total annual patients assuming all high-risk sepsis patients are tested with T2Direct Diagnostics and assuming (i) 90% of high risk patients receive appropriate therapy within hours of the presentation of symptoms, (ii) a 50% mortality rate reduction for patients who receive rapid appropriate therapy, and (iii) that each new detected patient saves \$22,800. This slide contains T2's estimates, which are not based on historical results and constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

T2Bacteria Pivotal Data Published in Annals of Internal Medicine

1,427 patient samples collected across 11 hospitals

Comparisons to Blood Culture:


- Detected 69 patient infections not detected by culture
- Provided results more than 2.5 days faster than culture (5.4 hours)
- 68% of patients with a BSI confirmed by T2 and blood culture could have benefitted from earlier rapid diagnostic result
- Noted advantage in detecting infected patients on antibiotics who were missed by blood culture





Emerging T2Bacteria Clinical Utility Data

- Cases from 7 ED & ICU studies aggregated here.
- 125/299 (42%) cases showed substantial clinical benefit of those evaluated under chart review
 - T2+: faster time to effective therapy
 - T2-: earlier antibiotic de-escalation
 - T2+: avoiding premature ED discharge/readmission
- 16% T2Bacteria positivity rate, range 13%-35% across all patients tested
- 2 cases of T2Bacteria helping avoid premature discharge and readmission in the ED
- A significant percentage of patients benefit from T2Bacteria results.






New Technology Add-on Payment by CMS



- The T2Bacteria Panel is the first, and only, in-vitro diagnostic test to ever receive approval from the US Centers for Medicare & Medicaid Services (CMS) for New Technology Add-on Payment (NTAP)
- CMS is the single largest payer for health care in the US
- The payment is in addition to the current diagnosis-related group (MS-DRG) reimbursement



"The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections." -United States CMS FY 2020 inpatient prospective payments system final rule

T2Biosystems[•]

T2Candida Panel is Changing Treatment Protocols

Growing number of real-world T2Candida success stories



- Study demonstrated \$2.3M in annual hospital savings
- Reduced median ICU length of stay by 7 days; overall stay by 4 days
- Most negative patients had antifungals discontinued or de-escalated saving \$\$.¹

Caring People. Inspiring Health

- Median length of stay reduced by 7 days
- Unnecessary antifungal therapy was avoided in >50% of patients
- Average net antifungal savings of ~\$195 for every patient tested²

- HUNTSVILLE HOSPITAL
- Pharmacy savings of ~\$280 per patient
- T2Candida detected 56% more positive patients than blood culture³

- Community Hospital
- 100% of patients who tested positive received appropriate therapy in <9 hours
- Therapy was discontinued for all patients who tested negative⁴

- 1. Wilson, N.M., Kenney, R.M., Tibbetts, R.J., et. al. T2 Magnetic Resonance Improves the Timely Management of Candidemia. Poster Presentation IDWeek 2016.
- 2. Estrada, S. J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.

Presentation IDWeek 2016.

3. Kateon, H., Edwards, J., Sawyer, A., et al. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital. Poster Presentation IDWeek 2016.

4. Patel, F. and Young, E. Antifungal Prescribing During Initial Implementation of Candidemia Early Detection and Species Identification Testing with T2Candida Panel. Poster



Significant Burden of Bacterial Infection and Sepsis

Payors should support and incentivize revised protocols

Add T2Bacteria & T2Candida

>90% of patients on the right targeted therapy within 6 to 8 hours



Representing \$27B in U.S. healthcare costs^{1,2}

~\$25,000 Cost Savings

Per patient if on right therapy within 24 hours³ **Billions of Dollars**

In savings for hospitals, including decreased readmissions⁴

50% Reduction

In mortality for patients with rapid effective treatment⁵ **Patients Benefit**

From reduction in long-term side-effects

```
4. See slide 11.
```

 Leibovici, L., Shraga, I., Drucker, M., et al. (1998). The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. Journal of internal medicine, 244(5), 379-386.



^{1.} Torio, C. M. and Moore, B. J. (2016). Statistical Brief# 204. Healthcare Cost and Utilization Project (HCUP). May.

^{2.} McDermott, K. W., Elixhauser, and A., and Sun, R. (2017). Statistical Brief# 225. Healthcare Cost and Utilization Project (HCUP). June.

^{3.} Estimated economic impact based on customer experience with T2Candida Panel; Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., and Munakata, J. (2015); and studies for target bacterial

species

Established Reimbursement Across Multiple Care Environments

Financially attractive in all settings

Point-of-Care Testing

Emergency Room Outpatient Settings

- CPT 87640, 87798
- Coverage if not admitted; other outpatient settings
- ER is most common setting

	T2Bacteria
Reimbursement	\$220
Cost of Test	\$150

In-Patient Hospital

Admitted from ER Admitted for Unrelated Procedure

- DRG 870, 871, 872; example DRG reimbursement: \$35,000¹
- NTAP max reimbursement of \$97.50 (65% of list price of T2Bacteria), starting 10/1/19

	T2Bacteria	T2Candida
Cost of Test	\$150	\$200
Cost After NTAP	\$52.50	
Percent of DRG	0.15%	0.6%
	0.75% c	of DRG
		T2Biosvstem

The T2Dx Impact

Improve the quality of patient care while reducing healthcare costs





Adoption Drives Revenue and Rapid Pay Back

Doing well by doing good

Typical High Risk Patients In Target Market						
Patients Suspected of Sepsis	3,000					
Patients Suspected of Fungal Infections	375					

Potential Hospital Utilization Scenario								
	Patients Tested	Price per Test	Total Revenue					
T2Bacteria	1,500	\$150	\$225,000					
T2Candida	375	\$200	\$75,000					
Annual Recurring	1,875		\$300,000					
T2Dx Instrument		\$100,000 unit price						

In this example, patients suspected of sepsis are screened with the T2Bacteria Panel in the ER and throughout portions of the hospital as part of a sepsis protocol.



Commercial Strategy

Global expansion of T2Direct Diagnostics driven by T2Bacteria Panel launch



United States

Direct Sales

- **Organization:** 15 sales reps and 6 medical affairs liaisons
- Target: 1,200 hospitals with the highest concentration of patients at risk for sepsis-related infections

International

small team of direct sales/marketing and

Distributor Sales in 35 Countries

14 distribution partners supported by

Expanding on the existing T2Dx installed base





field service personnel

Selected T2 Biosystems Customers



Comprehensive Commercial Tactics

Global expansion of T2Direct Diagnostics driven by T2Bacteria Panel launch



T2Resistance Panel

The first direct-from-blood detection of resistance markers

- Detection of 13 resistance genes from both Grampositive and Gram-negative pathogens from a single patient blood sample, without the wait for blood culture, in 3-5 hours
- Covers the most clinically important genes, including several listed on the CDC's Urgent Threat list for antibiotic resistance
- Utilizes **same T2Dx Instrument** as the T2Bacteria and T2Candida Panels
- Developed with the help of an award from CARB-X (funded by BARDA), the Wellcome Trust, and the National Institute of Allergy and Infectious Diseases (NIAID)
- Expected to be available for research use only in Q3 2019 and to receive CE Mark for commercial availability outside U.S. by the end of 2019

FDA Breakthrough Designation

- Granted "Breakthrough Device" designation by the FDA
- Allows T2 Biosystems to work closely with the FDA during the premarket review phase to ensure patients can have access to the benefits of this innovation as soon as possible

Powered by **CARB-X**





CORPORATE PRESENTATION

Research reported in this presentation is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust, as administrated by CARB-X. The content is solely the responsibility of T2 Biosystems and does not necessarily represent the official views of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, other funders, or CARB-X.

T2 Product & Pipeline Highlights

Enabled by Highly Sensitive Detection

		Powered by CARB-X					
T2Candida®	T2Bacteria [®]	T2Resistance	T2Candida auris	T2Lyme			
Sensitivity: 91.1% ² Specificity: 99.4% ²	Sensitivity: 95.4% ¹ Specificity: 98.0% ¹	FDA Breakthrough Device CE Mark/RUO 2019	Sensitivity: <u>></u> 89% Specificity: 98%	PPA: 78% NPA: 100%			
C. albicans C. tropicalis C. parapsilosis C. krusei C. glabrata	E. faecium S. aureus K. pneumoniae P. aeruginosa E. coli	mecA/C vanA/B CTXM-14/15 KPC OXA-48 Group NDM, VIM, IMP AmpC (CMY/DHA)	C. auris C. duobushaemulonii C. haemulonii	B. burgdorferi B. afzelii B. garinii Borellia spp.			
New FDA Product Code 1-3 CFU/mL LoD	New FDA Product Code 2-11 CFU/mL LoD	In Development 2-5 CFU/mL LoD	RUO; Validated by CDC for patient swabs, demonstrated performance in blood; ≤5 CFU/mL LoD	In pivotal study; 3-10 cells/mL LoD			
 T2Bacteria Pivotal Clinical Study. This is a combination of samples run in both prospective and contrived arms of study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study and the contrived arm an overall average PPA of 97%. Mylonakis, E., Clancy, C.J., Ostrosky-Zeichner, L., et al. (2015). Clinical Infectious Diseases 							

CORPORATE PRESENTATION

2. Mylonakis, E., Clancy, C.J., Ostrosky-Zeichner, L., et al. (2015). Clinical Infectious Diseases

3. Research reported in this presentation is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust, as administrated by CARB-X. The content is solely the responsibility of T2 Biosystems and does not necessarily represent the official views of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, other funders, or CARB-X.



T2Biosystems

Financial Summary¹

CORPORATE PRESENTATION

June 30, 2019						
	2Q19	\$1.8M				
Revenue	2Q18	\$3.9M				
	FY18	\$10.5M				
	2Q19	\$1.3M				
Product Revenue	2Q18	\$1.2M				
	FY18	\$4.8M				
Product Growth	YoY	8%				
Cash Burn	2Q19	\$8.9M				
Cash⁴		\$28.6M				
Common Shares Outstanding	2Q19	44.4M				

>5% Investors – As of June 30, 2018 ^{2,3}	
Canon Life Sciences	13.6%
Goldman Sachs	9.6%
Senvest Management	6.4%



Guidance

2019 Guidance					
2019 total revenue	\$8.7 - \$9.6 million				
Product revenue	\$5.7 - \$6.1 million				
3Q 2019:					
Product revenue	\$1.4 - \$1.5 million				
2019 T2Dx new contracts:	43 – 53				
3Q/4Q 2019 T2Dx new contracts:	10 – 15				
Quarterly operating expense: ¹	\$10.5 - \$11.5 million ²				

Breakeven Model						
Total revenue	\$65 - \$75 million					
Gross margin	~45 - 50%					

Excluding cost of product revenue.
 Including non-cash depreciation and stock based compensation of approximately \$3.0 million; contingent on closing a research collaboration
 * This slide contains T2's future goals and aspirations, which constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ

CORPORATE PRESENTATION

materially from those expressed or implied by such statements. See "Forward-Looking Statements" on slide 2.



Early 20th

century

1947

1959

1968

1985

Breakthroughs in Medical Diagnostics First and only FDA-cleared diagnostic to detect pathogens directly from blood

Blood

Cell

Culture

Counting

Immunoassay

Automated Chemistry

Analyzers

Technique

PCR








FAST@MPANY

Investment Highlights

A platform technology with multiple, billion-dollar franchise opportunities





Breakthrough Sepsis Pathogen Detection

Appendix

Corporate Presentation August 2019 (NASDAQ: TTOO)



Diagnostics Time to Result Influences Therapy


	(TIME (# of days)	Day 1		Day 2	Day 3		Day 4	Day 5
	Antibiotic Rx	Em	piric The	rapy	Gram Stai Directed Therapy		Species Directed Therapy	AST Directed Therapy	
R.	Blood Culture Dx	Inc	ubation	Gran Stair)	AST Testing	Wait for Additional B	
			-	37 hrs		72 hr	rs 94	l hrs	

3/ nrs

- Antibiotic administration rates range from 50% to 70% for patients with a blood culture draw ⁽¹⁻³⁾
- Only ~10% of patients suspected of sepsis yield a positive blood culture.
- Meta-analysis of 70 studies found empiric antibiotic therapy was inappropriate in 46.5% of patients⁴
- The proportion of patients on effective therapy after organism species ID has been shown to be >90%, demonstrating effectiveness of antibiogram-directed therapy based on species ID⁵
- Significant percentage of patients infected with resistant organisms die before AST results are available⁶

(1) Suberviola et al. J Clin Care 2016. (2) Karlsson et al. Int Care Med 2007; (3) Castellanos-Ortega et al. Crit Care Med 2010; (4) Paul et al. Antimicrob Agents 2010.95/ Ecern Set al. J Clin Micro 1994: (6) Satlin et al Antimicrob Agenst Chemo 2017. Average turn around times from: Huang et al. CID 2013; Nguyen et al. Annals Int Med 2019.





- T2MR Based tests enable more rapid targeted therapy based on species ID & resistance
- Across 3 studies, 94%-100% of patients are correctly treated after species ID, not after assessment of susceptibility testing, demonstrating effectiveness of antibiogram-directed therapy¹⁻³


2Biosvstems[®]

• Numerous studies indicate that this will reduce both LoS and mortality for infected patients

(1) Doern et al. *J Clin Micro* 1994; (2) Byl et al. Clin Infect Dis 1999; (3) Kerremans et al. J Clin Microbiol 2012 CORPORATE PRESENTATION

Time to Appropriate Therapy Impacts Survival

- Key predictor of survival and length of stay (LoS) for patients with bacteremia is time to effective therapy
- As many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment
- For every hour delay in time to appropriate therapy:
 - Survival decreases by 7.6% during septic shock¹
 - Relative odds of death increase by 4.0% during bacteremia²
- Reducing time to effective therapy has resulted in significant reductions in LoS, up to 8 days³⁻⁵
- Appropriate and rapid delivery of targeted antibiotics is critical for surviving sepsis⁶



Kumar A. et al., Crit Care Med 2006, 34:1286, N=2731

"Pursuit of the Holy Grail"* Rapid, Direct-from-Blood Pathogen & Resistance Results

Development	CE-Marked	FDA Cleared	US Clinical Use
	X tech of a & re 2.Sev deve	r decades, numerous nologies have pursue platform for direct-fro sistance results. veral have stopped or elopment programs to ure as a "direct" samp	ed the development m-blood pathogen shifted their post positive blood

Progress towards Culture Independent Tests


	LoD (CFU/mL)*	Clinical Sensitivity	Clinical Specificity	Comments	
T2Biosystems [•]	1-11	90% - per sample 90% - per result	90% - per sample 98% - per result	CE mark & FDA cleared ¹	
Roche	3-100	65%	86%	Manual test, CE mark only ²	
BRUKER RENISHAW	1-100	44%	87%	Automated test, CE-mark only ³	
Molzym	10-50	85%	48%	Manual test, CE mark only ⁴	
Abbott A Promise for Life	8-32	86% - per sample	86% - per sample	Withdrew FDA application, not on market ⁵	
	1,000,000	N/A	N/A	Focused on post-culture ⁶	
BIOMÉRIEUX BIOSFIRE	1,000	N/A	N/A	Maintained focus on post-culture ⁷	
microbiology in minutes*	N/A	N/A	N/A	Formal LoD data not disclosed ⁸	
KAKIUS	N/A – cfDNA	94% - per sample	40% - per sample	Send-out reference lab test9	

1. Nguyen et al. Annals Int Med 2019; 2. Roche Septifast labeling; Stevenson et al Health Technol Assess 2016; 3. McKeating JCP 2018; 4. Molzyme Sepsitest product labeling; 5. Metzgar et al PLOS ONE 2016; 6. PhenoTest 510(k) summary; 7. BCID product labelling; 8. Qvella AMP 2017 presentation; 9. Blauwkamp et al. Nature Micro 2019. *LoD based on ≥95% positivity rate for N≥20 replicates at a given titer level using CFU/mL assignment of cell solution spiked into blood.



Rapid Development of *C.auris* **T2MR Panel**

- ID of *Candida auris* has been hampered by the poor specificity, poor sensitivity and slow growth of organism
- Resulting in a delays in therapy for infected patients and delays in infection controls for colonized patients accelerating the spread of Candida auris The New Hork Times



- CDC approached T2 Biosystems with problem of prolonged culture for *C. auris*
- T2Candida auris Panel RUO (5 hr TAT) vs. Patient swab cultures (14 days TAT)
- T2Dx's installed at CDC Mycology laboratory for validation of use on patient skin swab samples¹⁻³
- 100% inclusivity of Clades I-IV, ≤5 CFU/mL LoD; ≥89% Sensitivity & 98% Specificity; 98% PPV, 89% NPV

1. Manning et al. "Automated Detection of Candida auris Direct from Whole Blood and Swab Specimens by T2MR" ID Week 2017

2. Sexton et al "Evaluation of a new T2 Magnetic Resonance assay for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples." Mycoses 2018

CORPORATE PRESENTATION

3. Sexton et al. "Evaluation of T2 Magnetic Resonance Candida auris Panel as a Rapid Diagnostic for this Emerging Multidrug Resistant Yeast in Clinical Skin-Swab Samples." ASM 2018.





DEADLY GERMS, LOST CURES

How a Chicago Woman Fell Victim to Candida Auris, a Drug-Resistant Fungus

The mysterious infection has appeared at hospitals around the world, but few institutions or families have discussed their experience.



Stephanie Spoor, center, with her husband, Gregory, left, during a bedside wedding ceremony of her son, Zack, to his new wife, Carley (right), at Northwestern Memorial Hospital in Chicago. Ms. Spoor died just a few days later. Spoor family photo

T2Lyme Clinical Performance

N= 21 Subjects	Tissue Culture				
Diagnostic Test	PPA	NPA	OPA		
T2Lyme (blood)	78%	100%	90%		
Tissue PCR	67%	100%	86%		
Seroconversion	67%	67%	67%		
2-Tier (Serology/WB)	56%	92%	76%		
Blood PCR	0%	100%	57%		
T2Lyme and 2-tier IgM	100%	92%	95%		

- True positive subjects were established by culturing *Borrelia* from an EM tissue sample.
- T2Lyme PPA was 78%, while CDC recommended 2-tier diagnosis PPA was 56%
- T2Lyme had higher accuracy (OPA) than all other methods; combination of T2Lyme & 2-tier IgM provided best overall clinical accuracy
- Blood PCR (PPA, 0%) failed to return any positive results
- NPA of T2Lyme was 100%, indicating greater specificity over serology results
 - We've tested >550 negative samples with no false-positive results



Comprehensive T2MR Panel for Bloodstream Infections

Result type	Ν	Results	
Pan-level	3	Gram positive bacteria, Gram negative bacteria, Fungi	
Genus level	11	Acinetobacter spp., Candida spp., Citrobacter spp., Enterobacter spp., Enterobacteraceae, Enterococcus spp., Listeria spp., Mycobacterium spp., Staphylococcus spp., Coag negative Staphylococcus spp., Streptococcus spp.	
Gram pos. species	6	E. faecium, E. faecalis, S. aureus, S. pneumoniae, S. pyogenes, S. viridans	
Gram neg. species	6	A. baumannii, E. coli, Enterobacter cloacae complex, H. influenzae, K. pneumoniae, P. aeruginosa	
Fungal Species	7	C. albicans, C. tropicalis, C. dublinensis, C. parapsilosis/C. metapsilosis/C. orthopsilosis, C. krusei, C. glabrata, C. auris	
Resistance genes	13	mecA/C, mefA/E, vanA/B, ermA/B, KPC, NDM, VIM, IMP, OXA, SHV, AmpC (CMY, DHA), CTX-M 14/15, TEM	

- T2MR Feasibility data in hand to support T2MR panel of ≥40 reported results
- Achieves inclusivity of ≥ 99% of infections caused by blood-borne bacterial and fungal pathogens
- "Pan-level" channels detect >250 pathogen species; ≤10 CFU/mL detection demonstrated for pan gram+/-
- Resistance markers provide coverage for <u>all</u> blood-borne CDC antibiotic resistance threats
- New T2MR detection technology developed to shorten turn-around time and reduce cost
- T2MR is proven for direct-from-whole-blood; new data shows feasibility for positive culture detection

